Pacific Bio为扩大全球经营 宣布韩国DNA Link公司为其亚洲经销商
FEBRUARY 08, 2012
Pacific Biosciences Expands Global Reach with New Asian Service Provider and Distributor
DNA Link is First Service Provider for PacBio RS Sequencing in Asia and the
First PacBio
®
RS Installation in Korea; Deal Brokered by New Distributor in Korea, MDxK
MENLO PARK, Calif. – February 8, 2012 – Pacific Biosciences of California, Inc., provider of
Single Molecule Real Time (SMRT
®
) sequencing products, today announced that DNA Link, Inc.
is the first commercial service provider for PacBio
®
RS sequencing in Asia and the first PacBio
RS installation in Korea. The deal was brokered by the company’s new distributor for Korea,
MDxK (Molecular Diagnostics Korea), Inc.
“We’re pleased to add the PacBio platform to our services portfolio,” said Dr. Jong E. Lee, CEO
of DNA Link. “Single Molecule Real-Time Sequencing Technology will open up a new era of
sequencing applications. We expect that it will help to uncover the mysteries of nature.”
Ram Laxman, Ph.D., Vice President of Sales for Asia at Pacific Biosciences commented: “We are
excited to expand our business in Asia and to have our first service provider in the region. We
trust their expertise to help handle many of the requests for single molecule, extremely long read
sequencing services from the Asian research community.”
The PacBio RS is a revolutionary DNA sequencing system that rapidly reveals new biological
insights by incorporating novel, single molecule sequencing techniques, advanced analytics, and
long readlengths. The PacBio RS is uniquely suited for genetic variant validation, providing
scientists with a high level of certainty due to high single molecule consensus accuracy and the
very long readlengths. The fast time to result enables researchers to complete validation
experiments rapidly, an important benefit for medical and clinical research. The system is also
ideal for cost effectively finishing genomes and for providing de novo assemblies of microbial
genomes such as infectious pathogens with strain-level resolution.
About DNA Link, Inc.
Established in March 2000, DNA Link, Inc. is a leading contract research service provider of
genomics studies. The company focuses on the study of genetic variations, especially on Single
Nucleotide Polymorphisms (SNPs) and the development of new drug targets. SNPs are the most
common form of genetic variation and are expected to play an essential role in the future of drug
development, diagnostics and other life science applications. As a genomics-based biotechnology
company, DNA Link, Inc. has a complete genotyping solution and large-scale resource of clinical
research. For more information visit www.dnalink.com.
About Pacific Biosciences, Inc.
Pacific Biosciences’ mission is to transform the way humankind acquires, processes and
interprets data from living systems through the design, development and commercialization of innovative tools for biological research. The company has developed a novel approach to
studying the synthesis and regulation of DNA, RNA and proteins. Combining recent advances in
nanofabrication, biochemistry, molecular biology, surface chemistry and optics, Pacific
Biosciences has created a powerful technology platform called single molecule, real-time, or
SMRT
®
, technology. SMRT technology enables real-time analysis of biomolecules with single
molecule resolution, which has the potential to transform the understanding of biological systems
by providing a window into these systems that has not previously been open for scientific study.
For more information about Pacific Biosciences, please visit www.pacificbiosciences.com. You
can also follow the company on Twitter: www.twitter.com/pacbio.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements may contain
words such as "believe," "may," "estimate," "anticipate," "continue," "intend," "expect," "plan,"
the negative of these terms, or other similar expressions, and include the assumptions that
underlie such statements. Such statements include, but are not limited to, statements regarding the
Company’s SMRT technology. These statements are subject to known and unknown risks and
uncertainties that could cause actual results to differ materially from those expressed or implied
by such statements, including but not limited to risks discussed from time to time in documents
Pacific Biosciences of California, Inc. has filed with the Securities and Exchange Commission,
including the risks identified under the section captioned "Risk Factors" in its recently filed
Quarterly Report on Form 10-Q. All forward-looking statements are based on estimates,
projections and assumptions as of the date hereof. Pacific Biosciences undertakes no obligation
to update any forward-looking statements.
Contacts:
For Pacific Biosciences:
Media: Investors:
Nicole Litchfield Trevin Rard
For Pacific Biosciences Pacific Biosciences
415.793.6468 650.521.8450
nicole@bioscribe.com ir@pacificbiosciences.com